GMDS: Key Enzyme in Glucose Metabolism Disorders (G2762)

Target Name: GMDS

NCBI ID: G2762

GMDS

GMDS: Key Enzyme in Glucose Metabolism Disorders

Growing evidence has shown that glucose metabolism disorders (GMA) are the pathogenesis of a variety of diseases. These diseases include diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and neurodegenerative diseases. The pathogenesis of glucose metabolism disorder (GMA) is not fully understood, however, studies have found that GMA plays a key role in the occurrence of the disease. In particular, GDP-mannose 4,6 dehydratase (GMDS) plays an important role in the pathogenesis of GMA.

The role of GMDS

GMDS is a glucose metabolism enzyme that participates in the process of glucose entering the liver for metabolism. Under normal circumstances, GMDS plays a vital role in the liver, helping the liver convert glucose into energy and transport it to various parts of the body for use. However, when GMA levels increase, GMDS activity also increases.

Studies have shown that elevated GMA levels are one of the main pathogenesis mechanisms of various diseases such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD) and neurodegenerative diseases. For example, in one study, scientists found that GMA levels were significantly elevated in the liver tissue of diabetic patients. In addition, elevated GMA levels can lead to fatty liver disease and liver damage, increasing the risk of fatty liver disease and cirrhosis.

In addition, elevated GMA levels can lead to neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease. In these diseases, accumulation of GMA can lead to neuronal death and exacerbate disease progression.

Treat GMA

Currently, treatments for GMA mainly include drug intervention and non-drug treatments.

medical treatement

Currently, some drugs, such as metformin, pioglitazone, and tetrapheniramine, have been shown to reduce GMA levels and thereby improve glucose metabolism. For example, metformin, a commonly used metformin-like drug, inhibits glucose transport in the liver, thereby lowering GMA levels. In addition, pioglitazone is an insulin sensitizer, which can increase the sensitivity of the liver to insulin, thereby reducing GMA levels.

non-pharmacological treatment

In addition to medication, some non-drug treatments can also reduce GMA levels, including lifestyle changes, diet, and exercise. For example, increasing physical activity can increase the body's sensitivity to insulin, thereby lowering GMA levels. In addition, dietary control, such as reducing the intake of high-calorie and high-fat foods, can also reduce GMA levels.

potential drug targets

Due to its important role in a variety of diseases, researchers are exploring GMA as a potential drug target. For example, scientists have discovered multiple possible drug targets on GMA and are studying their effects in depth.

in conclusion

In summary, GMDS plays an important role in the pathogenesis of glucose metabolism disorders. Elevated GMA levels are one of the main pathogenesis mechanisms of various diseases such as diabetes, obesity, non-alcoholic fatty liver disease (NAFLD), and neurodegenerative diseases. Currently, treatments for GMA mainly include drug intervention and non-drug treatments. Although GMA has high prospects as a drug target, more research is still needed to deeply reveal its mechanism of action in diseases and provide useful clues for disease treatment.

Protein Name: GDP-mannose 4,6-dehydratase

Functions: Catalyzes the conversion of GDP-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose

The "GMDS Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GMDS comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets